Stay updated on Carboplatin/Etoposide +/- Atezolizumab in ES-SCLC Clinical Trial
Sign up to get notified when there's something new on the Carboplatin/Etoposide +/- Atezolizumab in ES-SCLC Clinical Trial page.

Latest updates to the Carboplatin/Etoposide +/- Atezolizumab in ES-SCLC Clinical Trial page
- Check5 days agoChange DetectedA new revision entry v3.4.3 was added and the previous revision v3.4.2 was removed from the history.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check34 days agoChange DetectedAdded Revision: v3.4.2 to the history log and removed older notices including the lapse in government funding message and Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check41 days agoChange DetectedNotice added about government funding and the latest system revision to v3.4.1. The previous revision v3.4.0 was removed.SummaryDifference0.4%

- Check48 days agoChange DetectedThe UI now shows a Show glossary option and color-coded change indicators (green for additions, red for deletions) with updated footer text (No FEAR Act Data, Revision: v3.4.0). These changes are UI enhancements and do not modify the underlying study data.SummaryDifference0.5%

- Check62 days agoChange DetectedA new revision entry v3.3.4 was added to the History, and the previous entry v3.3.3 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check84 days agoChange DetectedThe record history shows the addition of Revision: v3.3.3 and removal of HHS Vulnerability Disclosure and Revision: v3.3.2, affecting only policy/footer items and versioning. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Carboplatin/Etoposide +/- Atezolizumab in ES-SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Carboplatin/Etoposide +/- Atezolizumab in ES-SCLC Clinical Trial page.